BETTER THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.008 USD | +2.83% |
|
0.00% | -95.90% |
| Mar. 21 | Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc | CI |
| Mar. 20 | Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index | CI |
Financials (USD)
| Sales 2023 * | - | Sales 2024 * | 3.8M | Capitalization | 424K |
|---|---|---|---|---|---|
| Net income 2023 * | -28M | Net income 2024 * | -47M | EV / Sales 2023 * | - |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 0.11 x |
| P/E ratio 2023 * |
-0.01
x | P/E ratio 2024 * |
-0.01
x | Employees | 54 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 46.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Better Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.83% | ||
| Current month | -42.86% | ||
| 1 month | -54.29% | ||
| 3 months | -95.69% | ||
| 6 months | -95.58% | ||
| Current year | -95.90% |
1 week
0.01
0.01
1 month
0.010.02
Current year
0.010.27
1 year
0.011.35
3 years
0.0129.40
5 years
0.0029.40
10 years
0.0029.40
| Managers | Title | Age | Since |
|---|---|---|---|
Andres Camacho
CTO | Chief Tech/Sci/R&D Officer | - | - |
Leslie Miller
AUD | Comptroller/Controller/Auditor | 43 | 21-09-30 |
| Corporate Officer/Principal | - | 22-10-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.008 | +2.83% | 1 653 |
| 24-04-24 | 0.00778 | +29.67% | 887,792 |
| 24-04-23 | 0.006 | -1.64% | 337,042 |
| 24-04-22 | 0.0061 | -1.61% | 299,438 |
| 24-04-19 | 0.0062 | -22.50% | 264,348 |
Delayed Quote OTC Markets, April 25, 2024 at 09:48 am EDT
More quotes
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.00778
USD
Average target price
1.5
USD
Spread / Average Target
+19,180.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -95.90% | 424K | |
| +1.06% | 43.84B | |
| +5.35% | 41.68B | |
| +45.04% | 41.25B | |
| -10.92% | 27.04B | |
| +7.97% | 25.53B | |
| -25.28% | 18.18B | |
| -3.11% | 12.29B | |
| +26.10% | 12.29B | |
| +6.97% | 11.15B |
- Stock Market
- Equities
- BTTX Stock
